Literature DB >> 11270973

Quantitative design of drug compatibility by weighted modification method.

Q S Zheng1, R Y Sun.   

Abstract

AIM: To set up a new method for designing and quantitatively analyzing drug compatibility.
METHODS: Drugs for compatibility were divided into 6 dose levels which were evenly distributed to 6 compound groups according to a fixed design. A new mathematical model was set up to fit the dose-effect data of 6 groups. The coefficients, obtained from the model, reflected the dose-effect relationship and the important degree of every drug in combination. According to the coefficients, the drugs in compatibility could be distinguished into principal drug, synergist, inferior, antagonist, and assistant. Because compatibility in the maximal effect group was nearly (or was) an optimal one in 6 groups, the doses in the group were taken as a base for further modification which considered interaction among drugs. The results of the modification were demonstrated by further experiment. This method was applied to design and to quantitatively analyze the compatibility of allantoin, metronidazole, and dexamethasone sodium phosphate by 2 effect indices in mice.
RESULTS: This new method was able to effectively determine important degree of drugs in combination, and to optimize their doses for designing compatibility.
CONCLUSION: This weighted modification method is a highly efficient, accurate, and practical means for designing and quantitatively analyzing drug compatibility.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 11270973

Source DB:  PubMed          Journal:  Zhongguo Yao Li Xue Bao        ISSN: 0253-9756


  3 in total

1.  The quaternary lidocaine derivative QX-314 in combination with bupivacaine for long-lasting nerve block: Efficacy, toxicity, and the optimal formulation in rats.

Authors:  Qinqin Yin; Jun Li; Qingshan Zheng; Xiaolin Yang; Rong Lv; Longxiang Ma; Jin Liu; Tao Zhu; Wensheng Zhang
Journal:  PLoS One       Date:  2017-03-23       Impact factor: 3.240

2.  Protamine zinc insulin combined with sodium selenite improves glycometabolism in the diabetic KKAy mice.

Authors:  Juan Lu; Wenjun Ji; Mei Zhao; Meng Wang; Wenhui Yan; Mingxia Chen; Shuting Ren; Bingxiang Yuan; Bing Wang; Lina Chen
Journal:  Sci Rep       Date:  2016-05-23       Impact factor: 4.379

3.  Protection against ischemia/reperfusion‑induced renal injury by co‑treatment with erythropoietin and sodium selenite.

Authors:  Lu Liu; Chao Liu; Lan Hou; Juan Lv; Fang Wu; Xuefei Yang; Shuting Ren; Wenjun Ji; Meng Wang; Lina Chen
Journal:  Mol Med Rep       Date:  2015-10-09       Impact factor: 2.952

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.